Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Massey

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
International Journal of Palliative Nursing|January 12, 2018
New innovative treatment in metastatic colorectal cancerAlison Massey
Marine Pollution Bulletin|November 1, 2006
Developing a saltmarsh classification tool for the European water framework directiveMike Best, Alison Massey, Amanda Prior
The Lancet. Oncology|January 29, 2010
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trialYu Jo Chua, Yolanda Barbachano, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerIan Chau, Gina Brown, David Cunningham, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
International Journal of Palliative Nursing|January 12, 2018
New innovative treatment in metastatic colorectal cancerAlison Massey
Marine Pollution Bulletin|November 1, 2006
Developing a saltmarsh classification tool for the European water framework directiveMike Best, Alison Massey, Amanda Prior
The Lancet. Oncology|January 29, 2010
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trialYu Jo Chua, Yolanda Barbachano, David Cunningham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerIan Chau, Gina Brown, David Cunningham, et al.
Pageof 1